Tumour angiogenesis factor in urological cancers.

The presence of a tumour angiogenesis factor (TAF) was investigated by bioassay and radioimmunoassay (RIA) in tissue and urine from patients with a variety of urological cancers. TAF was present in the majority of tumours studied by both methods and absent from controls. Our results suggest that RIA of urine for TAF may be applicable as a screening test for bladder cancer.